BioSpace News Archive

Avanir Pharmaceuticals, Inc., a pharmaceutical company committed to delivering innovative central nervous system (CNS) solutions, today announced its recognition as one of the 2020 Best Places to Work in Orange County—the only pharmaceutical company listed in the Orange County Business Journal’s 2020 “Best Places to Work in Orange County” Large Employer Category.

Myovant is a healthcare company developing innovative treatments for women’s health and prostate cancer. Myovant is currently evaluating their lead gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, in late-stage clinical programs for uterine fibroids, endometriosis, and prostate cancer.

An investigational drug for the treatment of Alzheimer’s disease shows significant improvement for patients with Lewy body dementia in a clinical trial that includes participants at the Pacific Neuroscience Institute located at Providence Saint John’s Health Center.

Astrotech Corporation (NASDAQ: ASTC), today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,887,906 shares of its common stock at a price of $2.15 per share for aggregate gross proceeds of $6.2 million.

Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today the company was named the 2020 David J. Gury Company of the Year by BioFlorida.

American Diabetes Month™ will kick off next week, and the American Diabetes Association® is asking the diabetes community to rise up! Right now, everything seems to be conspiring to try to make us feel powerless, afraid and small.

Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19 patient with lenzilumab

Health Canada is investigating the use of NSAIDs at 20 weeks or later in pregnancy and the rare, but serious, risk of kidney problems in an unborn baby that can lead to low levels of amniotic fluid and possible complications, in response to a Drug Safety Communication recently released by the U.S. FDA on this issue.

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2020 financial results and provide a corporate update before market open on Friday, November 6, 2020.

AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020.